Comparison of the effects of serotonin-norepinephrine reuptake inhibitors versus selective serotonin reuptake inhibitors on cerebrovascular events

Journal of Clinical Psychiatry

Volumn 77, Issue 1, 2016, Pages e1-e7

  Lee, Yen Chieh ^a   Lin, Chin Hsien ^b   Lin, Min Shung ^a   Lu, Yun ^c   Chang, Chia Hsuin ^b,c   Lin, Jou Wei ^b  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ANXIETY DISORDER; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; ICD-9-CM; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; AGED; CHEMICALLY INDUCED; COMPARATIVE STUDY; INTRACRANIAL HEMORRHAGES; MIDDLE AGED; RISK FACTOR; STROKE; TAIWAN;

AGED; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; RISK FACTORS; SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS; SEROTONIN UPTAKE INHIBITORS; STROKE; TAIWAN;

EID: 84957801735     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14m09394     Document Type: Article

References (32)

1. Kessler RC, Berglund P, Demler O, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105. doi:10.101/jama.289.23.3095 PubMed
2. Draper B, Berman K. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. Drugs Aging. 2008;25(6):501-519. doi:10.2165/02512-20825060-04 PubMed
3. Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10(9):732-747. doi:10.1017/S10928529019726 PubMed
4. Pan A, Sun Q, Okereke OI, et al. Depression and risk of stroke morbidity and mortality: a metaanalysis and systematic review. JAMA. 2011;306(11):1241-1249. doi:10.101/jama.201.1282 PubMed
5. Goldstein LB, Bushnell CD, Adams RJ, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research; Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(2):517-584.
6. Lee YC, Lin CH, Lin MS, et al. Effects of selective serotonin reuptake inhibitors versus tricyclic antidepressants on cerebrovascular events: a nationwide population-based cohort study. J Clin Psychopharmacol. 2013;33(6):782-789. doi:10.1097/JCP.0b013e31829c970e PubMed
7. Shin D, Oh YH, Eom CS, et al. Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. J Neurol. 2014;261(4):686-695. doi:10.107/s0415-014-7251-9 PubMed
8. Meijer WE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. 2004;164(21):2367-2370. doi:10.101/archinte.164.21.2367 PubMed
9. Andrade C, Sandarsh S, Chethan KB, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71(12):1565-1575. doi:10.408/JCP.09r05786blu PubMed
10. Licht CM, Penninx BW, de Geus EJ. Effects of antidepressants, but not psychopathology, on cardiac sympathetic control: a longitudinal study. Neuropsychopharmacology. 2012;37(11):2487-2495. doi:10.1038/np. 2012.107
11. Fiedorowicz JG, He J, Merikangas KR. The association between mood and anxiety disorders with vascular diseases and risk factors in a nationally representative sample. J Psychosom Res. 2011;70(2):145-154. doi:10.1016/j.jpsychores.2010.07.010 PubMed
12. Cheng CL, Kao YH, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20(3):236-242. doi:10.102/pds.2087 PubMed
13. Goldstein LB. Accuracy of ICD-9-CM coding for the identification of patients with acute ischemic stroke: effect of modifier codes. Stroke. 1998;29(8):1602-1604. doi:10.161/01. STR.29.8.1602 PubMed
14. Andrade SE, Harrold LR, Tjia J, et al. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):100-128. doi:10.102/pds.2312 PubMed
15. Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. 2012;79(18):1862-1865. doi:10.1212/WNL.0b013e318271f848 PubMed
16. Tseng YL, Chiang ML, Huang TF, et al. A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. Thromb Res. 2010;126(6):517-523. doi:10.1016/j.thromres.2010.09.017 PubMed
17. Hallbäck I, Hägg S, Eriksson AC, et al. In vitro effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation. Pharmacol Rep. 2012;64(4):979-983. doi:10.1016/S1734-140 (12) 70894-0 PubMed
18. Maschino F, Hurault-Delarue C, Chebbane L, et al; French Association of Regional Pharmacovigilance Centers. Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs: analysis of the French Spontaneous Reporting Database for a controversial ADR. Eur J Clin Pharmacol. 2012;68(11):1557-1560.
19. Wernicke J, Lledó A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebocontrolled studies. Drug Saf. 2007;30(5):437-455. doi:10.2165/02018-2073050-07 PubMed
20. Koschke M, Boettger MK, Schulz S, et al. Autonomy of autonomic dysfunction in major depression. Psychosom Med. 2009;71(8):852-860. doi:10.1097/PSY.0b013e3181b8b7a PubMed
21. Licht CM, de Geus EJ, Seldenrijk A, et al. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension. 2009;53(4):631-638. doi:10.161/HYPERTENSIONAHA.108.12698 PubMed
22. Licht CM, de Geus EJ, van Dyck R, et al. Longitudinal evidence for unfavorable effects of antidepressants on heart rate variability. Biol Psychiatry. 2010;68(9):861-868. doi:10.1016/j.biopsych.2010.06.032 PubMed
23. Abdelmawla AH, Langley RW, Szabadi E, et al. Comparison of the effects of nadolol and bisoprolol on the isoprenaline-evoked dilatation of the dorsal hand vein in man. Br J Clin Pharmacol. 2001;51(6):583-589. doi:10.1046/j.0306-5251.201.01404.x PubMed
24. Siepmann T, Ziemssen T, Mueck-Weymann M, et al. The effects of venlafaxine on autonomic functions in healthy volunteers. J Clin Psychopharmacol. 2007;27(6):687-691. doi:10.1097/jcp. 0b013e31815a25b PubMed
25. Shores MM, Pascualy M, Lewis NL, et al. Shortterm sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology. 2001;26(4):433-439. doi:10.1016/S0306-4530 (01) 02-6 PubMed
26. Scholz BA, Hammonds CL, Boomershine CS. Duloxetine for the management of fibromyalgia syndrome. J Pain Res. 2009;2:99-108.
27. Anderson HD, Pace WD, Libby AM, et al. Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study. Clin Ther. 2012;34(1):113-123. doi:10.1016/j.clinthera.201.1.024 PubMed
28. Turner MS, May DB, Arthur RR, et al. Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks. J Intern Med. 2007;261(3):205-213. doi:10.1/j.1365-2796.206.01720.x PubMed
29. de Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry. 2008;65(7):795-803. doi:10.101/archpsyc.65.7.795 PubMed
30. Labos C, Dasgupta K, Nedjar H, et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ. 2011;183(16):1835-1843. doi:10.1503/cmaj.10912 PubMed
31. Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol. 2009;104(6):1475-1482. doi:10.1038/ajg.209.128 PubMed
32. Löppönen P, Tetri S, Juvela S, et al. Association between warfarin combined with serotoninmodulating antidepressants and increased case fatality in primary intracerebral hemorrhage: a population-based study. J Neurosurg. 2014;120(6):1358-1363. doi:10.3171/2013.12. JNS131898 PubMed